HuGE Literature Finder
Records
1
-
12
Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion 2018 97 (2): 154-162. Shiotani Akiko, Katsumata Ryo, Gouda Kyousuke, Fukushima Shinya, Nakato Rui, Murao Takahisa, Ishii Manabu, Fujita Minoru, Matsumoto Hiroshi, Sakakibara Takas |
Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori. Medical science monitor : international medical journal of experimental and clinical research 2017 Jun 23 2701-2707. Lin Yun-An, Wang Hong, Gu Zhu-Jun, Wang Wen-Jia, Zeng Xiao-Yan, Du Yan-Lei, Ying Song-Song, Zhang Bo-H |
Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. Basic & clinical pharmacology & toxicology 2016 Sep . Karaca R O, Kalkisim S, Altinbas A, Kilincalp S, Yuksel I, Goktas M T, Yasar U, Bozkurt A, Babaoglu M |
Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2014 Jul 33 (4): 330-5. Settin Ahmad, Abdalla Ahmad Fathy, Al-Hussaini Ayman S, El-Baz Rizk, Galal A |
Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. Asian Pacific journal of cancer prevention : APJCP 2014 15 (24): 10957-60. Jainan Wannapa, Vilaichone Ratha-Ko |
Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy 2011 Mar 31 (3): 227-38. Yang Jyh-Chin, Wang Hong-Long, Chern Herng-Der, Shun Chia-Tung, Lin Bor-Ru, Lin Chun-Jung, Wang Teh-Ho |
Personalized treatment in the eradication therapy for Helicobacter pylori. International journal of molecular medicine 2011 Feb 27 (2): 255-61. Jinda Sayaka, Nakatani Kaname, Nishioka Junji, Yasuda Kazunari, Soya Yoshihiro, Hayashi Amiko, Wada Hideo, Nobori Tsuto |
Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians. The Indian journal of medical research 2009 Oct 130 (4): 437-43. Chaudhry A S, Kochhar R, Kohli K |
Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2007 Nov 11 (11): 1506-14; discussion 1514. Zambon Carlo-Federico, Fasolo Michela, Basso Daniela, D'Odorico Anna, Stranges Alessia, Navaglia Filippo, Fogar Paola, Greco Eliana, Schiavon Stefania, Padoan Andrea, Fadi Elisa, Sturniolo Giacomo Carlo, Plebani Mario, Pedrazzoli Serg |
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Alimentary pharmacology & therapeutics 2005 Nov 22 (10): 1033-40. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, Hishida A, Ishizaki |
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese]. Zhonghua nei ke za zhi [Chinese journal of internal medicine] 2004 Jan 43 (1): 13-5. He XX, Zhao YH, Hao YT |
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2001 Nov 33 (8): 671-5. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 22, 2022
- Content source: